HCPCS Q5170 is officially defined as "Injection, aflibercept-boav (eydenzelt), biosimilar, 1 mg." HCPCS Q5170 is referenced in 2 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island and Blue Cross Blue Shield of North Dakota. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q5170 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Related
Get alerts for changes like this
Save a search and receive a daily digest whenever a new policy change matches your filters.